Skip to search formSkip to main contentSkip to account menu

BMS 232632

Known as: 232632, BMS, BMS-232632, BMS232632 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Recommendations for a highly active antiretroviral therapy (HAART) in either pretreated patients or symptomatic patients with an… 
Highly Cited
2002
Highly Cited
2002
ABSTRACT The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other… 
Review
2002
Review
2002
  • P. Piliero
  • Expert Opinion on Investigational Drugs
  • 2002
  • Corpus ID: 20374074
The introduction of HIV-1 protease inhibitors in 1995 ushered in the era of highly active antiretroviral therapy. For the first… 
2001
2001
BMS-232632 is a potent human immunodeficiency type 1 (HIV-1) protease inhibitor with a half-life that allows for once-daily… 
2001
2001
  • G. Witherell
  • Current opinion in investigational drugs
  • 2001
  • Corpus ID: 21294499
BMS-232632, an azapeptide HIV protease inhibitor, is in development by Bristol-Myers Squibb (BMS), under license from Novartis… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT BMS-232632 is an azapeptide human immunodeficiency virus type 1 (HIV-1) protease (Prt) inhibitor that exhibits potent… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT BMS-232632 is an azapeptide human immunodeficiency virus (HIV) type 1 (HIV-1) protease inhibitor that displays potent…